Edison Pharmaceuticals, Inc.

Galileo Pharmaceuticals, Inc.

Bioelectron Technology Corporation

Ptc Therapeutics, Inc.

Johnson & Johnson Consumer Companies, Inc.

J&j Consumer Companies, Inc.

Ampere Life Sciences, Inc.

Guy M. Miller

Sidney M. Hecht

Guy M Miller

Bing Wang

Sidney M Hecht

Viktoria Kheifets

Sekhar S Boddupalli

Lesley A Brown

Wei Zhang

Stephen F Flaim

Kieron E Wesson

Paul Mollard

Sylvain Gilat

Stephen D Phinney

Jian Chen

Yong-Kang Zhang

Khalid Mahmood

Orion D Jankowski

Ughetta Del Balzo

Darlene M Dreon

Jiangao Song

Xianfeng Li

Peggy Beinlich

Satyanarayana Janagani

Sekhar Boddupalli

Gary Binyamin

Steven Bobzin

Xiangfeng Li

Sekhar Bodupalli

Diego Martinelli

Carlo Dionisi-Vici

Enrico Bertini

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.

Treatment of pervasive developmental disorders with redox-active therapeutics

The present invention relates to methods of treating Leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.

Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones

Methods of treating or suppressing oxidative stress diseases and symptoms related to oxidative stress affecting normal electron flow in the cells or caused by reactive oxygen species with redox-active therapeutics. Use of redox-active therapeutics for the reduction, suppression or treatment of oxidative stress induced by chemical agents such as contrast agents and other nephrotoxic agents, by radiation exposure, and by disruptions in the transport of oxygen to tissues, is disclosed.

Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD&#x2014;not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.

A method of reducing the appearance of skin conditions associated with loss of skin tightness, skin firmness, or dark circles under the eyes with topical compositions comprising compounds of any of the Formulae I or Ia as described herein, is disclosed.

Methods for treatment of dermatological conditions

Cytoprotective compounds, many of which are phenolic derivatives characterized by a substituted phenol having certain conjugated bonds, are useful in the treatment of certain ischemic or inflammatory conditions, including but not limited to stroke, myocardial infarction, congestive heart failure, and skin disorders characterized by inflammation or oxidative damage. They are also useful in the manufacture of pharmaceutical and cosmetic formulations for the treatment of such conditions.

Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods

Growing community of inventors

Monte Sereno, CA, United States of America

Guy M Miller